FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal tumor types worldwide. BET inhibitors display anti-tumor activity in pancreatic cancer, however the cells often develop resistance after a long-term treatment and the underlying molecular basis is not fully understood. MET...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Exp Clin Cancer Res
Hlavní autoři: Wang, Bo, Fan, Ping, Zhao, Jingyuan, Wu, Heyu, Jin, Xin, Wu, Heshui
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2018
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6131902/
https://ncbi.nlm.nih.gov/pubmed/30201002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-018-0888-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky